Last update July 31, 2017

Teicoplanin

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Antibacterial glycopeptide, administered via intravenous or intramuscular
injection.

Its pharmacokinetic data (high molecular weight, high percentage of plasma protein binding and no oral bioavailability) explain the negligible passage into milk observed (Fraissinet 2017) and the absence of side effects in a 52-day-old infant whose mother was being treated with teicoplanin (Kaplan 2017).

Not being absorbed orally, there would be no passage to the infant's plasma from ingested breast milk.
It is an antibiotic that is administered, if necessary, to newborns.

The possible negativity of cultures in febrile infants whose mothers take antibiotics should be taken into account, as well as the possibility of gastroenteritis due to altered intestinal flora.

Alternatives

We do not have alternatives for Teicoplanin since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Teicoplanin is also known as


Teicoplanin in other languages or writings:

Group

Teicoplanin belongs to this group or family:

Tradenames

Main tradenames from several countries containing Teicoplanin in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 1.500 -1.900 daltons
Protein Binding 88 - 95 %
VD 0.7 - 1.4 l/Kg
Tmax 2 hours
60 - 170 hours
M/P ratio 0.08 -
Theoretical Dose 0.14 mg/Kg/d
Relative Dose 1.4 %

References

  1. Kaplan YC, Keskin-Arslan E, Acar S, Erol-Coskun H. Teicoplanin Use During Breastfeeding. Breastfeed Med. 2017 Mar;12:124. Abstract
  2. Fraissinet F, Lesourd M, Naudoux N, Metsu D, Gandia P. Pharmacokinetics of Teicoplanin in a Breastfeeding Mother. Breastfeed Med. 2017 Abstract
  3. AEMPS. Teicoplanina. Ficha técnica. 2016 Full text (in our servers)
  4. Sanofi. Teicoplanin. Drug Summary. 2009 Full text (in our servers)
  5. Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 2000 Abstract

Total visits

6,697

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM